Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide.
Parikh M, Tangen C, Hussain MHA, Gupta S, Callis S, Jo Y, Harzstark A, Paller CJ, George S, Zibelman MR, Cheng HH, Maughan BL, Zhang J, Pachynski RK, Bryce AH, Lin DW, Quinn DI, Lerner SP, Thompson IM, Dorff TB, Lara PN, Agarwal N.
Parikh M, et al. Among authors: maughan bl.
Eur Urol Oncol. 2024 Oct;7(5):1097-1104. doi: 10.1016/j.euo.2024.03.001. Epub 2024 Mar 23.
Eur Urol Oncol. 2024.
PMID: 38523017
Free article.
Clinical Trial.